HLS Therapeutics Inc (HLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HLS Therapeutics Inc (HLS) has a cash flow conversion efficiency ratio of 0.105x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$6.44 Million ≈ $4.66 Million USD) by net assets (CA$61.56 Million ≈ $44.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see HLS Therapeutics Inc (HLS) total market value for the company's overall valuation and market capitalisation.
HLS Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how HLS Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
HLS Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HLS Therapeutics Inc ranked by their cash flow conversion efficiency. Explore HLS Therapeutics Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GaeaSoft Corp
KQ:051160
|
0.034x |
|
Namsun Alumini
KO:008350
|
-0.021x |
|
Infragreen Group Ltd
AU:IFN
|
-0.004x |
|
Favelle Favco Bhd
KLSE:7229
|
-0.008x |
|
ATW Technology Inc
TWO:8097
|
-0.004x |
|
Shanghai Phoenix Enterprise Group Co Ltd B
SHG:900916
|
0.036x |
|
Infant Bacterial Therapeutics AB (publ)
ST:IBT-B
|
-0.420x |
|
Right Way Industrial Co Ltd
TW:1506
|
0.008x |
Annual Cash Flow Conversion Efficiency for HLS Therapeutics Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of HLS Therapeutics Inc from 1996 to 2025. View current stock price of HLS Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$61.56 Million ≈ $44.53 Million |
CA$16.02 Million ≈ $11.59 Million |
0.260x | +131.95% |
| 2024-12-31 | CA$71.34 Million ≈ $51.61 Million |
CA$8.00 Million ≈ $5.79 Million |
0.112x | -30.59% |
| 2023-12-31 | CA$97.70 Million ≈ $70.67 Million |
CA$15.79 Million ≈ $11.42 Million |
0.162x | +19.54% |
| 2022-12-31 | CA$125.32 Million ≈ $90.65 Million |
CA$16.94 Million ≈ $12.26 Million |
0.135x | +32.27% |
| 2021-12-31 | CA$160.74 Million ≈ $116.27 Million |
CA$16.43 Million ≈ $11.88 Million |
0.102x | +85.14% |
| 2020-12-31 | CA$169.25 Million ≈ $122.43 Million |
CA$9.34 Million ≈ $6.76 Million |
0.055x | -62.75% |
| 2019-12-31 | CA$178.20 Million ≈ $128.91 Million |
CA$26.41 Million ≈ $19.10 Million |
0.148x | -28.28% |
| 2018-12-31 | CA$158.49 Million ≈ $114.65 Million |
CA$32.75 Million ≈ $23.69 Million |
0.207x | +37.20% |
| 2017-12-31 | CA$180.38 Million ≈ $130.49 Million |
CA$27.17 Million ≈ $19.65 Million |
0.151x | +3562.31% |
| 2016-12-31 | CA$24.97 Million ≈ $18.06 Million |
CA$-108.62K ≈ $-78.58K |
-0.004x | +96.16% |
| 2015-12-31 | CA$26.03 Million ≈ $18.83 Million |
CA$-2.94 Million ≈ $-2.13 Million |
-0.113x | -129.05% |
| 2014-12-31 | CA$46.75 Million ≈ $33.82 Million |
CA$18.21 Million ≈ $13.17 Million |
0.389x | -12.46% |
| 2013-12-31 | CA$40.53 Million ≈ $29.32 Million |
CA$18.03 Million ≈ $13.04 Million |
0.445x | -14.10% |
| 2012-12-31 | CA$40.99 Million ≈ $29.65 Million |
CA$21.23 Million ≈ $15.36 Million |
0.518x | -5.88% |
| 2011-12-31 | CA$32.56 Million ≈ $23.55 Million |
CA$17.92 Million ≈ $12.96 Million |
0.550x | -27.03% |
| 2010-12-31 | CA$33.23 Million ≈ $24.04 Million |
CA$25.06 Million ≈ $18.13 Million |
0.754x | +408.59% |
| 2009-12-31 | CA$35.90 Million ≈ $25.97 Million |
CA$5.32 Million ≈ $3.85 Million |
0.148x | -24.36% |
| 2008-12-31 | CA$28.33 Million ≈ $20.50 Million |
CA$5.55 Million ≈ $4.02 Million |
0.196x | -55.32% |
| 2007-12-31 | CA$50.09 Million ≈ $36.24 Million |
CA$21.98 Million ≈ $15.90 Million |
0.439x | +1816.11% |
| 2006-12-31 | CA$30.72 Million ≈ $22.23 Million |
CA$703.50K ≈ $508.90K |
0.023x | -94.50% |
| 2005-12-31 | CA$30.02 Million ≈ $21.72 Million |
CA$12.50 Million ≈ $9.04 Million |
0.416x | +208.31% |
| 2004-12-31 | CA$18.42 Million ≈ $13.33 Million |
CA$2.49 Million ≈ $1.80 Million |
0.135x | -26.74% |
| 2003-12-31 | CA$26.67 Million ≈ $19.30 Million |
CA$4.92 Million ≈ $3.56 Million |
0.184x | -35.68% |
| 2002-12-31 | CA$24.47 Million ≈ $17.70 Million |
CA$7.01 Million ≈ $5.07 Million |
0.287x | +135.36% |
| 2001-12-31 | CA$24.45 Million ≈ $17.69 Million |
CA$2.98 Million ≈ $2.15 Million |
0.122x | -76.93% |
| 2000-12-31 | CA$12.48 Million ≈ $9.03 Million |
CA$6.59 Million ≈ $4.77 Million |
0.528x | +64.79% |
| 1999-12-31 | CA$14.22 Million ≈ $10.29 Million |
CA$4.56 Million ≈ $3.30 Million |
0.320x | +5033.98% |
| 1998-12-31 | CA$10.01 Million ≈ $7.24 Million |
CA$-64.99K ≈ $-47.01K |
-0.006x | -101.99% |
| 1997-12-31 | CA$16.91 Million ≈ $12.23 Million |
CA$5.52 Million ≈ $3.99 Million |
0.326x | -70.75% |
| 1996-12-31 | CA$8.31 Million ≈ $6.01 Million |
CA$9.27 Million ≈ $6.71 Million |
1.116x | -- |
About HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances … Read more